Assessment Of Policies, Determinants And Characteristics Of Generic Medicines Entry Into The Malaysian Pharmaceutical Market

The Malaysia healthcare system relies on the availability of generic equivalents of innovator medicines to curtail the rising pharmaceutical expenditure. This study assesses the dimensions and dynamics of generic medicines entry following patent expiration on the innovator drug products in Malaysia....

Full description

Bibliographic Details
Main Author: Fatokun, Omotayo Oladuntoye
Format: Thesis
Language:English
Published: 2014
Subjects:
Online Access:http://eprints.usm.my/46094/1/Fatokun%20Omotayo%20Oladuntoye24.pdf
_version_ 1825835277288996864
author Fatokun, Omotayo Oladuntoye
author_facet Fatokun, Omotayo Oladuntoye
author_sort Fatokun, Omotayo Oladuntoye
collection USM
description The Malaysia healthcare system relies on the availability of generic equivalents of innovator medicines to curtail the rising pharmaceutical expenditure. This study assesses the dimensions and dynamics of generic medicines entry following patent expiration on the innovator drug products in Malaysia. This was a mixed-methods study. The findings of this research revealed 14 categories of policies and regulatory measures with varying effects on generic entry in Malaysia. The mail survey yielded a usable response rate of 53.8% (14/26) following four successive mailings. Reliability coefficients for the multi-item entry decisions and entry barriers variables were 0.62 and 0.82 respectively. The major factors driving generic development and entry decisions in Malaysia were pre-patent expiration market value of innovator’s products (Meanrank= 3.75, M=4.14, SD=1.03), cost of generic development and approval (Mean-rank= 3.04, M=3.50, SD=1.40) and compatibility of the new generic medicine with firms’ existing products range (Mean-rank=2.79, M=3.64, SD=1.2). The innovator product’s pre-patent expiration market value was a significant entry driver for domestic-market oriented generic firms as compared with export-market oriented firms (U=0.00, Z=- 2.36, p=0.01). The Major barriers to generic medicines development and market entry in Malaysia were patent clustering by innovator firms (Mean-rank=7.96, M=4.07, SD=0.83) and earlier market entry of imported generics (Mean-rank=7.75, M=4.07, SD=0.73).
first_indexed 2024-03-06T15:35:19Z
format Thesis
id usm.eprints-46094
institution Universiti Sains Malaysia
language English
last_indexed 2024-03-06T15:35:19Z
publishDate 2014
record_format dspace
spelling usm.eprints-460942020-02-05T08:13:43Z http://eprints.usm.my/46094/ Assessment Of Policies, Determinants And Characteristics Of Generic Medicines Entry Into The Malaysian Pharmaceutical Market Fatokun, Omotayo Oladuntoye RS1-441 Pharmacy and materia medica The Malaysia healthcare system relies on the availability of generic equivalents of innovator medicines to curtail the rising pharmaceutical expenditure. This study assesses the dimensions and dynamics of generic medicines entry following patent expiration on the innovator drug products in Malaysia. This was a mixed-methods study. The findings of this research revealed 14 categories of policies and regulatory measures with varying effects on generic entry in Malaysia. The mail survey yielded a usable response rate of 53.8% (14/26) following four successive mailings. Reliability coefficients for the multi-item entry decisions and entry barriers variables were 0.62 and 0.82 respectively. The major factors driving generic development and entry decisions in Malaysia were pre-patent expiration market value of innovator’s products (Meanrank= 3.75, M=4.14, SD=1.03), cost of generic development and approval (Mean-rank= 3.04, M=3.50, SD=1.40) and compatibility of the new generic medicine with firms’ existing products range (Mean-rank=2.79, M=3.64, SD=1.2). The innovator product’s pre-patent expiration market value was a significant entry driver for domestic-market oriented generic firms as compared with export-market oriented firms (U=0.00, Z=- 2.36, p=0.01). The Major barriers to generic medicines development and market entry in Malaysia were patent clustering by innovator firms (Mean-rank=7.96, M=4.07, SD=0.83) and earlier market entry of imported generics (Mean-rank=7.75, M=4.07, SD=0.73). 2014-02 Thesis NonPeerReviewed application/pdf en http://eprints.usm.my/46094/1/Fatokun%20Omotayo%20Oladuntoye24.pdf Fatokun, Omotayo Oladuntoye (2014) Assessment Of Policies, Determinants And Characteristics Of Generic Medicines Entry Into The Malaysian Pharmaceutical Market. PhD thesis, Universiti Sains Malaysia.
spellingShingle RS1-441 Pharmacy and materia medica
Fatokun, Omotayo Oladuntoye
Assessment Of Policies, Determinants And Characteristics Of Generic Medicines Entry Into The Malaysian Pharmaceutical Market
title Assessment Of Policies, Determinants And Characteristics Of Generic Medicines Entry Into The Malaysian Pharmaceutical Market
title_full Assessment Of Policies, Determinants And Characteristics Of Generic Medicines Entry Into The Malaysian Pharmaceutical Market
title_fullStr Assessment Of Policies, Determinants And Characteristics Of Generic Medicines Entry Into The Malaysian Pharmaceutical Market
title_full_unstemmed Assessment Of Policies, Determinants And Characteristics Of Generic Medicines Entry Into The Malaysian Pharmaceutical Market
title_short Assessment Of Policies, Determinants And Characteristics Of Generic Medicines Entry Into The Malaysian Pharmaceutical Market
title_sort assessment of policies determinants and characteristics of generic medicines entry into the malaysian pharmaceutical market
topic RS1-441 Pharmacy and materia medica
url http://eprints.usm.my/46094/1/Fatokun%20Omotayo%20Oladuntoye24.pdf
work_keys_str_mv AT fatokunomotayooladuntoye assessmentofpoliciesdeterminantsandcharacteristicsofgenericmedicinesentryintothemalaysianpharmaceuticalmarket